p62-Mediated Aggresome Formation in Chemo-Treated Carcinoma

Results from experiments using cisplatin-resistant (CDDP) cancer cell lines suggest that malfunctioning of proteasome plays a role in resistance to platinum-based drugs. ß5, a subunit of proteasome complex, was markedly reduced in CDDP cells, which is associated with increased p62 protein expression...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical pathology Vol. 144; no. suppl_2; p. A305
Main Authors Zheng, Wei, Palacios, Maria Franco, Fung, Kar-Ming, Guo, Ruifeng, Ramesh, Rajagopal, Zhao, Lichao
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford University Press 01.10.2015
Subjects
Breast cancer
Drug resistance
Metastasis
Proteasomes
Online AccessGet full text

Cover

More Information
Summary:Results from experiments using cisplatin-resistant (CDDP) cancer cell lines suggest that malfunctioning of proteasome plays a role in resistance to platinum-based drugs. ß5, a subunit of proteasome complex, was markedly reduced in CDDP cells, which is associated with increased p62 protein expression. p62 binds and aggregates intracellular accumulated polyubiquitinated proteins into aggresomes and prevents cell death. To our knowledge, there is no prior data in the literature suggesting that proteasome could contribute to cancer drug resistance. 49 primary and metastatic lung and breast carcinoma tissue blocks were retrieved from archive.
ISSN:0002-9173
1943-7722
DOI:10.1093/ajcp/144.suppl2.305